放射外科在MD安德森肿瘤中心的实践及进展

Practice and progress of stereotactic ablative radiotherapy in MD Anderson Cancer Center

非小细胞肺癌（NSCLC）是我国最常见的恶性肿瘤之一.立体放射外科（SABR）,也称立体定向放疗（SBRT）,是一种无创性治疗,在现代精确的影像引导技术下给予局部肿瘤以高剂量、低分割的放射治疗,可获得超过90％的肿瘤局部控制率,已成为不可切除早期NSCLC的标准治疗,也是可手术早期NSCLC的治疗选择之一.美国德州大学MD安德森肿瘤中心（MDACC）作为全美肿瘤治疗排名第一的机构,对NSCLC的放射治疗进行了一系列颇具影响力的SABR临床试验和研究,促进了SABR在早期和晚期NSCLC中的应用.本文将MDACC对SABR的临床应用、研究结果和进展做一总结.

Image-guided stereotactic ablative radiotherapy （SABR,also known as stereotactic body radiotherapy） is a non-invasive treatment by delivering ablative doses of radiation over one to ten fractions to tumors,and it achieves local control in excess of 90%.SABR has become a standard treatment for medically inoperable and an option for operable clinical early-stage non-small-cell lung cancer （NSCLC）.The university of Texas MD Anderson Cancer Center （MDACC）,as a top institute of cancer research and treatment worldwide,has conducted a series of influential SABR clinical trials and researches.The results have greatly promoted the application of SABR in early-and advanced-stage NSCLC.Here we summarize the clinical application,study progresses and findings of SABR for NSCLC in MDACC.